- Home
- CNTX vs MRCC Comparison
CNTX vs MRCC Comparison
Compare CNTX & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- MRCC
- Stock Information
- Founded
- CNTX 2015
- MRCC 2011
- Country
- CNTX United States
- MRCC United States
- Employees
- CNTX N/A
- MRCC N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- MRCC Investment Managers
- Sector
- CNTX Health Care
- MRCC Finance
- Exchange
- CNTX Nasdaq
- MRCC Nasdaq
- Market Cap
- CNTX 149.6M
- MRCC 174.8M
- IPO Year
- CNTX 2021
- MRCC 2012
- Fundamental
- Price
- CNTX $1.30
- MRCC $8.44
- Analyst Decision
- CNTX Strong Buy
- MRCC Strong Buy
- Analyst Count
- CNTX 3
- MRCC 1
- Target Price
- CNTX $6.83
- MRCC $9.00
- AVG Volume (30 Days)
- CNTX 210.1K
- MRCC 60.2K
- Earning Date
- CNTX 11-06-2024
- MRCC 11-12-2024
- Dividend Yield
- CNTX N/A
- MRCC 11.83%
- EPS Growth
- CNTX N/A
- MRCC 298.01
- EPS
- CNTX N/A
- MRCC 0.60
- Revenue
- CNTX N/A
- MRCC $62,007,000.00
- Revenue This Year
- CNTX N/A
- MRCC N/A
- Revenue Next Year
- CNTX N/A
- MRCC N/A
- P/E Ratio
- CNTX N/A
- MRCC $14.09
- Revenue Growth
- CNTX N/A
- MRCC N/A
- 52 Week Low
- CNTX $0.77
- MRCC $6.77
- 52 Week High
- CNTX $2.75
- MRCC $8.64
- Technical
- Relative Strength Index (RSI)
- CNTX 25.94
- MRCC 63.42
- Support Level
- CNTX $1.56
- MRCC $8.20
- Resistance Level
- CNTX $2.32
- MRCC $8.64
- Average True Range (ATR)
- CNTX 0.16
- MRCC 0.16
- MACD
- CNTX -0.07
- MRCC 0.05
- Stochastic Oscillator
- CNTX 17.88
- MRCC 75.90
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.